FDA
-
-
-
-
-
-
-
Hims & Hers Health (HIMS) stock: Should you buy the dip after massive selloff?
-
-
-
-
-
-
-
Novo Nordisk sues Hims & Hers over patent infringement
-
-
-
-
-
-
-
European shares close at record high as AI worries ease, UniCredit gains
-
-
-
-
-
-
-
Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*
-
-
-
-
-
-
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
-
-
-
-
-
-
Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office
-
-
-
-
-
-
-
Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

